

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	09/869,709	SIPPEL ET AL.	
	Examiner	Art Unit	
	Zachariah Lucas	1648	

All Participants:

(1) Zachariah Lucas.

(2) Richard M. Lebovitz.

Status of Application: _____

(3) _____

(4) _____

Date of Interview: 30 August 2005

Time: _____

Type of Interview:

- ☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No
 If Yes, provide a brief description:

Part I.

Rejection(s) discussed:
NA

Claims discussed:
42, 79, and 37, 38, 45, 46, 48-59, and 61-73

Prior art documents discussed:
NA

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:
See Continuation Sheet

Part III.

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.


(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The Examiner indicated that the claims would be in condition for allowance

- 1) upon the cancellation of withdrawn claims 37, 38, 45, 46, 48-59, and 61-73,
- 2) if claim 42 was amended to clarify what is being claimed, and
- 3) if claim 79 was cancelled or amended to clarify how it is different from claim 1.

It was agreed that claims 37, 38, 45, 46, 48-59, 61-73, and 79 would be cancelled, and that claim 42 would be amended to read as follows:

- - Claim 42 A screening method for testing the suitability of a plurality of test substances as ligands for a ligand-binding domain of a receptor, characterized in that the assay method of claim 35 is employed for the screening. - - These amendments would be made by Examiner's Amendment.